Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers

To evaluate the safety profile of AR882 based on incidence of adverse events

Incidence of adverse events following multiple doses of AR882

Time frame: 22 Days

To evaluate the safety profile of AR882 based on incidence of abnormal laboratory findings

Incidence of abnormal laboratory findings following multiple doses of AR882

Time frame: 22 Days

To evaluate the safety profile of AR882 based on incidence of abnormal electrocardiogram findings

Incidence of abnormal electrocardiogram findings following multiple doses of AR882

Time frame: 22 Days

To evaluate the safety profile of AR882 based on incidence of abnormal vital signs findings

Incidence of abnormal vital signs findings following multiple doses of AR882

Time frame: 22 Days

Area under the curve (AUC) for plasma AR882

Profile from plasma in terms of AUC following multiple doses of AR882

Time frame: 15 Days

Time to maximum plasma concentration (Tmax) for AR882

Profile from plasma in terms of Tmax following multiple doses of AR882

Time frame: 15 Days

Maximum plasma concentration (Cmax) for AR882

Profile from plasma in terms of Cmax following multiple doses of AR882

Time frame: 15 Days

Apparent terminal half-life (t1/2) for AR882

Profile from plasma in terms of t1/2 following multiple doses of AR882